Method for improving specific activity of fumonisins degrading enzyme, mutant and application
By performing specific amino acid sequence mutations on fumartoxin degradation enzymes, an efficient fumartoxin degradation enzyme mutant was developed, which solved the limitations of removing fumartoxin in the existing technology, and achieved a safe and efficient degradation effect. in agriculture and food industries.
Patent Information
- Application Number
- CN202410988544.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-12
AI Technical Summary
Existing physical and chemical methods have limitations when removing fuma toxins. Chemical methods will introduce new chemical substances to increase safety risks. Physical methods have high conditions and affect food quality. Although biodegradation methods are mild, they are not specific and efficient. It cannot effectively degrade fumar toxin.
A mutant of fumartoxin degradation enzyme with increased vitality and its genes and recombinant strains were developed. By mutation of the original fumartoxin degradation enzyme in a specific amino acid sequence, it improves its degradation ability, including Q229S, Q229G, Q229A, etc. Mutants, encoding genes are inserted into recombinant vectors and expressed to form efficient fumartoxin degradation enzyme preparations.
The relative vitality of mutant enzymes is significantly improved, which can efficiently degrade fumar toxins and reduce the harm to animals and human health. It is suitable for agriculture, feed and food industries, and provides a safe and effective degradation method.
Smart Images

Figure CN118931875A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a method for improving the specific activity of a fumonisin degrading enzyme, a mutant and an application thereof. Background Art
[0002] Fumonisin (FB) is a water-soluble secondary metabolite produced by Fusarium spp. under specific conditions. Fumonisin is a diester compound composed of polyhydric alcohol and tricarboxylic acid. The main active functional groups in the structure are primary amine, tricarboxylic acid, hydroxyl and aliphatic skeleton, which are closely related to their toxic effects. Studies have shown that fumonisin can cause rat kidney tumors and liver cancer, equine leukoencephalomalacia (ELEM), porcine pulmonary edema (PPE), etc., and is closely related to the incidence of human esophageal cancer. So far, 28 fumonisin analogs have been discovered and divided into four categories, namely FA, FB, FC and FP. In the B series, the most commonly found are fumonisin B1 (FB1), B2 (FB2) and B3 (FB3). Among them, FB1 accounts for about 70%-80% of the amount in nature, and its toxicity is the strongest and the pollution is the most extensive. Fumonisins can be removed by physical and chemical methods, but chemical methods have great limitations. Although they can reduce the content of FB1, they will introduce new chemical substances and increase safety risks. In addition, the EU also prohibits the use of chemical methods to eliminate mycotoxins. Physical methods can remove a certain amount of fumonisins, but they require high conditions and are easy to change the quality and flavor of food. The biodegradation method has a mild reaction to degrade fumonisins, strong specificity, and high specificity, and has a very broad application prospect.
[0003] Mycotoxin pollution is becoming increasingly serious around the world, which causes a waste of precious food resources and is carcinogenic to humans. Therefore, the development of enzyme preparations that degrade mycotoxins can effectively curb the production of toxins in contaminated food crops and recover economic losses. Summary of the invention
[0004] In order to utilize biodegradation to degrade fumonisin, the present invention is proposed and completed.
[0005] The object of the present invention is to provide a fumonisin degrading enzyme mutant with improved specific activity.
[0006] Another object of the present invention is to provide a fumonisin degrading enzyme gene with improved specific activity.
[0007] Another object of the present invention is to provide a recombinant expression vector comprising the above gene.
[0008] Another object of the present invention is to provide a recombinant strain comprising the above gene.
[0009] Another object of the present invention is to provide a method for preparing fumonisin-degrading enzyme.
[0010] Another object of the present invention is to provide a method for increasing the specific activity of fumonisin degrading enzyme.
[0011] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S according to a specific embodiment of the present invention is shown in SEQ ID NO:1.
[0012] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S, and the genome sequence of the gene is shown in SEQ ID NO:2.
[0013] The amino acid sequence of the fumonisin degrading enzyme mutant Q229G according to a specific embodiment of the present invention is shown in SEQ ID NO:3.
[0014] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229G, the nucleotide sequence of which is shown in SEQ ID NO:4.
[0015] The amino acid sequence of the fumonisin degrading enzyme mutant Q229A according to a specific embodiment of the present invention is shown in SEQ ID NO:5.
[0016] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229A. The genome sequence of the gene is shown in SEQ ID NO:6.
[0017] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / S231A according to a specific embodiment of the present invention is shown in SEQ ID NO:7.
[0018] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / S231A. The genome sequence of the gene is shown in SEQ ID NO:8.
[0019] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / D255S according to a specific embodiment of the present invention is shown in SEQ ID NO:9.
[0020] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / D255S. The genome sequence of the gene is shown in SEQ ID NO:10.
[0021] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / S231G according to a specific embodiment of the present invention is shown in SEQ ID NO:11.
[0022] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / S231G. The genome sequence of the gene is shown in SEQ ID NO:12.
[0023] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / A233R according to a specific embodiment of the present invention is shown in SEQ ID NO:13.
[0024] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / A233R. The genome sequence of the gene is shown in SEQ ID NO:14.
[0025] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / S234G according to a specific embodiment of the present invention is shown in SEQ ID NO:15.
[0026] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / S234G. The genome sequence of the gene is shown in SEQ ID NO:16.
[0027] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / V441T according to a specific embodiment of the present invention is shown in SEQ ID NO:17.
[0028] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / V441T. The genome sequence of the gene is shown in SEQ ID NO:18.
[0029] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / G443R according to a specific embodiment of the present invention is shown in SEQ ID NO:19.
[0030] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / G443R, and the genome sequence of the gene is shown in SEQ ID NO:20.
[0031] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / D346G according to a specific embodiment of the present invention is shown in SEQ ID NO:21.
[0032] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / D346G. The genome sequence of the gene is shown in SEQ ID NO:22.
[0033] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / G348R according to a specific embodiment of the present invention is shown in SEQ ID NO:23.
[0034] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / G348R, and the genome sequence of the gene is shown in SEQ ID NO:24.
[0035] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / S256G according to a specific embodiment of the present invention is shown in SEQ ID NO:25.
[0036] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / S256G, the genome sequence of which is shown in SEQ ID NO:26.
[0037] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / N344E according to a specific embodiment of the present invention is shown in SEQ ID NO:27.
[0038] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / N344E. The genome sequence of the gene is shown in SEQ ID NO:28.
[0039] The amino acid sequence of the fumonisin degrading enzyme mutant Q229S / R516S according to a specific embodiment of the present invention is shown in SEQ ID NO:29.
[0040] The present invention provides a gene encoding the fumonisin degrading enzyme mutant Q229S / R516S, and the genome sequence of the gene is shown in SEQ ID NO:30.
[0041] The present invention also provides a recombinant vector comprising the above-mentioned fumonisin degrading enzyme mutant encoding gene, which is inserted between appropriate restriction enzyme cleavage sites of the expression vector so that its nucleic acid sequence can be operably connected to the expression regulatory sequence.
[0042] The method for improving the specific activity of fumonisin degrading enzyme according to the present invention comprises the following steps:
[0043] The following mutations were made to the equine toxin degrading enzyme whose amino acid sequence is shown in SEQ ID NO: 31:
[0044] Q229S, Q229G or Q229A.
[0045] According to the method for improving the specific activity of fumonisin degrading enzyme of the present invention, when Q229S is performed on the fumonisin degrading enzyme with an amino acid sequence as shown in SEQ ID NO: 11, the method further comprises the step of performing S231A, D255S, S231G, A233R, S234G, V441T, G443R, D346G, G348R, S256G, N344E or R516S mutation.
[0046] The amino acid sequence of the fumonisin degrading enzyme Fum37 according to a specific embodiment of the present invention is shown in SEQ ID NO:31.
[0047] The present invention provides a gene encoding the fumonisin degrading enzyme Fum37, and the genome sequence of the gene is shown in SEQ ID NO:32.
[0048] The present invention also provides a recombinant strain comprising the above-mentioned fumonisin degrading enzyme mutants Q229S, Q229G, Q229A, Q229S / S231A, Q229S / D255S, Q229S / S231G, Q229S / A233R, Q229S / S234G, Q229S / V441T, Q229S / G443R, Q229S / D346G, Q229S / G348R, Q229S / S256G, Q229S / N344E and Q229S / R516S encoding genes, preferably the strain is Escherichia coli.
[0049] The present invention also provides a method for preparing a fumonisin degrading enzyme, comprising the following steps:
[0050] (1) transforming a host cell with a recombinant vector containing a gene encoding a fumonisin degrading enzyme mutation to obtain a recombinant strain;
[0051] (2) culturing the recombinant strain to induce the expression of fumonisin-degrading enzymes;
[0052] (3) Isolate and purify the obtained fumonisin degrading enzyme mutant enzyme.
[0053] Among them, the host cell is preferably a colon cell, preferably Escherichia coli BL21 (DE3).
[0054] The present invention also provides the application of the fumonisin degrading enzyme mutant, especially in the application of degrading fumonisin.
[0055] The fumonisin degrading enzyme mutants Q229S, Q229G, Q229A, Q229S / S231A, Q229S / D255S, Q229S / S231G, Q229S / A233R, Q229S / S234G, Q229S / V441T, Q229S / G443R, Q229S / D346G, Q229S / G348R, Q229S / S256G, Q229S / N344E and Q229S / R516S of the present invention are compared with the degradation ability of fumonisin degrading enzyme Fum37 on FB1, and the relative activity of each fumonisin degrading enzyme mutant is higher than the relative activity of fumonisin degrading enzyme Fum37. By using the method of the present invention, a fumonisin degrading enzyme mutant with excellent properties can be obtained. The enzyme can be applied to agriculture, feed, food and other industries to reduce the harm of fumonisin to animal and human health. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1 The figure is the protein electrophoresis diagram of fumonisin degrading enzyme mutants, wherein M: Marker; 1: fumonisin degrading enzyme wild type WT; 2: fumonisin degrading enzyme mutant Q229S; 3: fumonisin degrading enzyme mutant Q229G; 4: fumonisin degrading enzyme mutant Q229A; 5: fumonisin degrading enzyme mutant Q229S / S231A; 6: fumonisin degrading enzyme mutant Q229S / D255S; 7: fumonisin degrading enzyme mutant Q229S / S231G; 8: fumonisin degrading enzyme mutant Q229S / A233R; 9: Fumonisin degrading enzyme mutant Q229S / S234G; 10: Fumonisin degrading enzyme mutant Q229S / V441T; 11: Fumonisin degrading enzyme mutant Q229S / G443R; 12: Fumonisin degrading enzyme mutant Q229S / D346G; 13: Fumonisin degrading enzyme mutant Q229S / G348R; 14: Fumonisin degrading enzyme mutant Q229S / S256G; 15: Fumonisin degrading enzyme mutant Q229S / N344E; 16: Fumonisin degrading enzyme mutant Q229S / R516S;
[0057] Figure 2 The optimal reaction temperature and optimal pH of the fumonisin-degrading enzyme mutants are shown. DETAILED DESCRIPTION
[0058] The experimental materials and reagents involved in the following examples are:
[0059] 1. Strains and vectors: Escherichia coli expression vector pET28a(+) and strain BL21(DE3);
[0060] 2. Culture medium: Escherichia coli culture medium LB (1% peptone, 0.5% yeast extract, 1% NaCl, pH 7.0).
[0061] Example 1 Preparation of recombinant fumonisin degrading enzyme mutants Q229S, Q229G, Q229A, Q229S / S231A, Q229S / D255S, Q229S / S231G, Q229S / A233R, Q229S / S234G, Q229S / V441T, Q229S / G443R, Q229S / D346G, Q229S / G348R, Q229S / S256G, Q229S / N344E and Q229S / R516S.
[0062] Using fumonisin degrading enzyme Fum37 as a template, the recombinant plasmids pET28a(+)-Fum37-Q229S, pET28a(+)-Fum37-Q229G, pET28a(+)-Fum37-Q229A, pET28a(+)-Fum37-Q229S / S231A, pET28a(+)-Fum37-Q229S / D255S, pET28a(+)-Fum37-Q229S / S231G, pET28a(+)-Fum37-Q229S / A233R, pET28a(+)-Fum37-Q229S / S234G, pET28a(+)-Fum37-Q229S / V441T, pET28a(+)-Fum37-Q229S / G443R, pET28a(+)-Fum37-Q229S / D346G, pET28a(+)-Fum37-Q229S / G348R, pET28a(+)-Fum37-Q229S / S256G, pET28a(+)-Fum37-Q229S / N344E and pET28a(+)-Fum37-Q229S / R516S. Transformed into Escherichia coli BL21(DE3) to obtain recombinant Escherichia coli strains BL21(DE3) / Fum37-Q229S, BL21(DE3) / Fum37-Q229G, BL21(DE3) / Fum37-Q229A, BL21(DE3) / Fum37-Q229S / S231A and BL21(DE3) / Fum37-Q229S / D255S, BL21(DE3) / Fum37-Q229S / S231G, BL21(DE3) / Fum37-Q229S / A233R, BL21(DE3) / Fum37-Q229S / Fum37-Q229S / S234G, BL21(DE3) / Fum37-Q229S / V441T, BL21(DE3) / Fum37-Q229S / G443R, BL21(DE3) / Fum37-Q229S / D346G, BL21(DE3) / Fum37-Q229S / G348R, BL21(DE3) / Fum37-Q229S / S256G, BL21(DE3) / Fum37-Q229S / N344E, and BL21(DE3) / Fum37-Q229S / R516S.
[0063] Take the BL21 (DE3) strain containing the recombinant plasmid and inoculate it into 100 mL LB culture medium. After shaking culture at 37°C and 220 rpm for 2-3 hours, the OD 600When the pH value was 0.6-0.8, IPTG was added at a final concentration of 1 mM and the cells were induced at 25°C for 20 h. After induction, the cells were collected by centrifugation at 4°C. The supernatant was collected by ultrasonic disruption and purified by nickel column. The results of SDS-PAGE showed that the recombinant fumonisin degrading enzyme was expressed in E. coli. Figure 1 As shown, lane 1 is the wild type WT of fumonisin degrading enzyme, lane 2 is the mutant Q229S of fumonisin degrading enzyme, lane 3 is the mutant Q229G of fumonisin degrading enzyme, lane 4 is the pure enzyme solution of the mutant Q229A of fumonisin degrading enzyme, lane 5 is the mutant Q229S / S231A of fumonisin degrading enzyme, and lane 6 is the pure enzyme solution of the mutant Q229S / D255S of fumonisin degrading enzyme. Lane 7 is the fumonisin degrading enzyme mutant Q229S / S231G, lane 8 is the fumonisin degrading enzyme mutant Q229S / A233R, lane 9 is the fumonisin degrading enzyme mutant Q229S / S234G, lane 10 is the fumonisin degrading enzyme mutant Q229S / V441T, lane 11 is the fumonisin degrading enzyme mutant Q229S / G443R, lane 12 is the fumonisin degrading enzyme mutant Q229S / D346G, lane 13 is the fumonisin degrading enzyme mutant Q229S / G348R, lane 14 is the fumonisin degrading enzyme mutant Q229S / S256G, lane 15 is the fumonisin degrading enzyme mutant Q229S / N344E and lane 16 is the fumonisin degrading enzyme mutant Q229S / R516S.
[0064] Example 2 Determination of the activity of FB1 degradation by fumonisin degrading enzyme mutation
[0065] 2.1 High performance liquid chromatography was used to detect the enzymatic activity of the fumonisin degrading enzyme mutant enzyme. The specific method is as follows:
[0066] (1) FB1 standard stock solution: weigh 1 mg of the standard product and dissolve it in 20 mL of acetonitrile and water (1:1) to prepare a standard solution with a concentration of 50 μg / mL and store at -4°C.
[0067] (2) Sample preparation: Take 45 μL of the purified fumonisin degrading enzyme mutant enzyme solution, add 5 μL of FB1 standard stock solution to make the final concentration of FB1 5 μg / mL, and react at 37°C in a dark water bath for 20 min;
[0068] (3) Sample derivatization: Take 50 μL of the sample to be tested, add 200 μL of 50% acetonitrile and 250 μL of OPA derivatization solution, mix for 30 seconds, inject within 2 minutes of derivatization, and filter the membrane for testing. The enzyme activity of the fumonisin degrading enzyme mutant is determined by comparing the peak graph with the FB1 standard. As shown in Table 1 , the relative enzyme activity of the fumonisin degrading enzyme Fum37 was 100%, the relative enzyme activity of the mutant Q229S was 156.26%, the relative enzyme activity of the mutant Q229G was 135.36%, the relative enzyme activity of the mutant Q229A was 130.35%, the relative enzyme activity of the mutant Q229S / S231A was 143.73%, the relative enzyme activity of the mutant Q229S / D255S was 123.45%, the relative enzyme activity of the mutant Q229S / S231G was 152.15%, the relative enzyme activity of the mutant Q229S / A233R was 170.34%, and the relative enzyme activity of the mutant Q229S / The relative enzyme activity of S234G was 180.35%, the relative enzyme activity of mutant Q229S / V441T was 134.98%, the relative enzyme activity of mutant Q229S / G443R was 190.12%, the relative enzyme activity of mutant Q229S / D346G was 289.11%, the relative enzyme activity of mutant Q229S / G348R was 190.12%, the relative enzyme activity of mutant Q229S / S256G was 132.24%, the relative enzyme activity of mutant Q229S / R516S was 193.21% and the relative enzyme activity of mutant Q229S / N344E was 130.23%.
[0069] Table 1
[0070]
[0071] 2.2 Determination of the optimal temperature of fumonisin-degrading enzyme mutants
[0072] Take FB1 as substrate, take 5uL substrate and add 45uL enzyme solution, the final concentration is 5ug / mL, react for 20min in citric acid-sodium hydrogen phosphate buffer (pH7.0) buffer system and different temperatures, then boil in boiling water for 10min to inactivate the enzyme. After cooling to room temperature, pass through the membrane and wait for high performance liquid chromatography detection. Figure 2 As shown, the optimum temperature of fumonisin-degrading enzyme and its mutants is 40°C.
[0073] 2.3 Determination of the optimal pH of fumonisin-degrading enzyme mutants
[0074] The purified recombinant fumonisin degrading enzyme mutant was subjected to enzymatic reaction in different pH buffers to determine its optimal pH. The buffer gradient of the selected buffer solution was: 100mM citric acid-disodium hydrogen phosphate (pH3.0-8.0), 100mM Tris-Hcl (pH8.0-9.0), 100mM glycine-NaOH (pH 9.0-12.0). The fumonisin degrading enzyme mutant was reacted with the substrate FB1 (final concentration of 5μg / mL) in the above different buffers at 40℃ for 20min, boiled in boiling water for 10min, and detected by high performance liquid chromatography. The results are shown in Figure 2 As shown, the wild-type fumonisin degrading enzyme and the fumonisin degrading enzyme mutants Q229S, Q229G, Q229A, Q229S / S231A, Q229S / D255S, Q229S / S231G, Q229S / A233R, Q229S / S234G, Q229S / V441T, Q229S / G443R, Q229S / D346G, Q229S / G348R, Q229S / S256G, Q229S / N344E and Q229S / R516S all maintained >80% relative activity between 8.0 and 9.0, and the mutants did not significantly change the optimal pH range of action.
[0075] (1) Fumonisin degradation rate: expressed as the ratio of the peak area m0 of the hydrolyzed fumonisin HFB1 to the peak area m of the fumonisin FB1 standard;
[0076]
[0077] (2) Wild-type relative activity: mutant degradation rate w o It is expressed as a ratio to the wild-type degradation rate w;
[0078]
[0079] The above embodiments are only used to understand the technical solution of the present application and do not limit the protection scope of the present application.
Claims
1. A fumonisin degrading enzyme mutant with improved specific activity, characterized in that: The amino acid sequence of the mutant is shown in SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:
5.
2. A fumonisin degrading enzyme mutant with improved specific activity, characterized in that: The amino acid sequence of the mutant is shown in SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, or SEQ ID NO:
29.
3. A fumonisin degrading enzyme gene, characterized in that: The gene encodes the fumonisin degrading enzyme mutant with improved specific activity as claimed in claim 1 or 2.
4. The fumonisin degrading enzyme gene according to claim 3, characterized in that: The nucleotide sequence of the gene needs to be as shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28 or SEQ ID NO:
30.
5. A recombinant vector comprising the fumonisin degrading enzyme gene according to claim 3.
6. A recombinant strain comprising the fumonisin degrading enzyme gene according to claim 3.
7. Use of the fumonisin degrading enzyme mutant with improved specific activity according to claim 1 or 2.
8. Use of the fumonisin degrading enzyme mutant with improved specific activity according to claim 1 or 2 for degrading fumonisin.
9. A method for increasing the specific activity of a fumonisin-degrading enzyme, characterized in that: The method comprises the following steps: performing Q229S, Q229G or Q229A mutation on the equine toxin degrading enzyme whose amino acid sequence is shown in SEQ ID NO:
31.
10. The method for improving the specific activity of fumonisin degrading enzyme according to claim 9, characterized in that: When Q229S is performed on the equine toxin degrading enzyme with an amino acid sequence as shown in SEQ ID NO: 31, the method further comprises the step of performing S231A, D255S, S231G, A233R, S234G, V441T, G443R, D346G, G348R, S256G, N344E or R516S mutation.
Citation Information
Cited By
Fumonisins degrading enzyme mutant with improved specific activity and thermal stability as well as coding gene and application of fumonisins degrading enzyme mutant
CN119876051A
